FDG-PET/CT versus 99mTc-MDP bone scan and contrast-enhanced CT in metastatic renal cell cancer receiving a combination of standard vascular endothelial growth factor (VEGF)-targeted therapy and a radiopharmaceutical

Conclusions: These preliminary data suggest that measuring response of mRCC early after starting treatment using metabolic imaging criteria (PERCIST 1.0) may identify a sub-group of patients with a better outcome: PFS was not reached in the PMR group during the study period. Bone and soft tissue lesions in mRCC behaved similarly on metabolic imaging, whereas most bone lesions remained unchanged on anatomic imaging. While more data are needed to determine whether ceCT or PET/CT is the optimal imaging method for monitoring bone and soft tissue response in mRCC patients with bone metastases, our data suggest that both may be better determinants of response than traditional bone scan. Table 1. Outcomes by PERCIST 1.1, RECIST 1.0, and MD Anderson Bone Response CriteriaOS (months)OS P valuesPFS (months)PFS P valuesPERCIST 1.1 PMR16.6NRPERCIST 1.1 SMD/PMD8.7P=0.195.5P=0.07RECIST 1.0 SD17.78.3RECIST 1.0 PD7.5P=0.023.7P=0.16MD Anderson CR/PR14.28.3MD Anderson SD/PD17.7P=0.5012.8P=0.96
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Posters Source Type: research